INVESTMENTS IN VARIABLE INTEREST ENTITIES	6 Months Ended
INVESTMENTS IN VARIABLE INTEREST ENTITIES	Jun. 30, 2026
Variable Interest Entities [Abstract]
INVESTMENTS IN VARIABLE INTEREST ENTITIES	6. INVESTMENTS IN VARIABLE INTEREST ENTITIES The Company reviews its investments in other entities to determine whether the Company is the primary beneficiary of a VIE. The Company would be the primary beneficiary of the VIE, and would be required to consolidate the VIE, if it has the power to direct the significant activities of the entity and the obligation to absorb losses or receive benefits from the entity that may be significant to the VIE. The Company's maximum loss exposure to VIEs, prior to the exercise of options to acquire the entities, is limited to its investment in the VIEs, which include equity investments, options to acquire, and promissory notes. Consolidated VIE In May 2026, the Company amended several agreements, including an option agreement with a medical device company (the “Consolidated VIE”), which was previously an unconsolidated VIE of the Company. As a result of the amendments, the Company determined it has become the primary beneficiary of the Consolidated VIE and it has been consolidated in the Company’s condensed consolidated financial statements as of May 2026. See Note 7 for additional information. Unconsolidated VIEs Edwards has relationships with various VIEs that it does not consolidate as Edwards lacks the power to direct the activities that significantly impact the economic success of these entities. In January 2026, the Company invested in a convertible promissory note of $45.0 million in JenaValve Technology, Inc. pursuant to an Agreement and Plan of Merger executed in July 2024. In December 2024, the Company entered into an option agreement and an amended preferred stock purchase agreement with a medical technology company. The Company had previously made an investment in preferred equity securities of the medical technology company under a prior preferred stock purchase agreement in 2021. As of both June 30, 2026 and December 31, 2025, the Company had invested $35.0 million in the medical technology company's preferred equity securities (included in Long-term Investments), and advanced $16.0 million under the promissory note agreement (included in Other Assets). As of December 31, 2025, the Company had invested $40.0 million in the option to acquire the medical technology company. In June 2026, as a result of the Company’s decision to terminate the option agreement, the Company recognized a $40.0 million loss on impairment for the option during the three months ended June 30, 2026. The charge is included in Loss on Impairment within non-operating income. In February 2019, the Company entered into a warrant agreement with a medical device company and paid $35.0 million for an option to acquire the medical device company. Since then, the Company has advanced $77.5 million under the convertible promissory note agreement as of December 31, 2025 (both included in Other Assets). In March 2026, as a result of the carrying amount of investments not being recoverable, the Company recognized a $123.6 million loss on impairment, including $11.1 million of accrued interest, during the six months ended June 30, 2026. The charge is included in Loss on Impairment within non-operating income. In addition, Edwards has made equity investments through the NMTC program in limited liability companies that are considered VIEs. For more information, see Note 5.